<h1>Paper Summary</h1>

<!--META_START-->

<p>Title: A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing  </p>

<p>Authors: Jonathan S. Berg, Ann Katherine M. Foreman, Julianne M. O’Daniel, Jessica K. Booker, Lacey Boshe, Timothy Carey, Kristy R. Crooks, Brian C. Jensen, Eric T. Juengst, Kristy Lee, Daniel K. Nelson, Bradford C. Powell, Cynthia M. Powell, Myra I. Roche, Cecile Skrzynia, Natasha T. Strande, Karen E. Weck, Kirk C. Wilhelmsen, James P. Evans  </p>

<p>DOI: 10.1038/gim.2015.104  </p>

<p>Year: 2016  </p>

<p>Publication Type: Journal Article  </p>

<p>Discipline/Domain: Genomic Medicine / Medical Genetics  </p>

<p>Subdomain/Topic: Clinical Actionability Assessment in Genomic Sequencing  </p>

<p>Eligibility: Eligible  </p>

<p>Overall Relevance Score: 95  </p>

<p>Operationalization Score: 100  </p>

<p>Contains Definition of Actionability: Yes  </p>

<p>Contains Systematic Features/Dimensions: Yes  </p>

<p>Contains Explainability: Yes  </p>

<p>Contains Interpretability: Yes  </p>

<p>Contains Framework/Model: Yes  </p>

<p>Operationalization Present: Yes  </p>

<p>Primary Methodology: Conceptual Framework Development and Application  </p>

<p>Study Context: Evaluation of incidental/secondary findings in clinical genome-scale sequencing  </p>

<p>Geographic/Institutional Context: University of North Carolina at Chapel Hill, USA  </p>

<p>Target Users/Stakeholders: Clinical geneticists, genomic testing laboratories, healthcare providers, policy-makers  </p>

<p>Primary Contribution Type: Framework/method for assessing clinical actionability of gene–disease pairs  </p>

<p>CL: Yes  </p>

<p>CR: Yes  </p>

<p>FE: Yes  </p>

<p>TI: Partial  </p>

<p>EX: Yes  </p>

<p>GA: Partial  </p>

<p>Reason if Not Eligible: N/A  </p>

<!--META_END-->

<p><strong>Title:</strong>  </p>

<p>A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing  </p>

<p><strong>Authors:</strong>  </p>

<p>Jonathan S. Berg et al.  </p>

<p><strong>DOI:</strong>  </p>

<p>10.1038/gim.2015.104  </p>

<p><strong>Year:</strong>  </p>

<p>2016  </p>

<p><strong>Publication Type:</strong>  </p>

<p>Journal Article  </p>

<p><strong>Discipline/Domain:</strong>  </p>

<p>Genomic Medicine / Medical Genetics  </p>

<p><strong>Subdomain/Topic:</strong>  </p>

<p>Clinical Actionability Assessment in Genomic Sequencing  </p>

<p><strong>Contextual Background:</strong>  </p>

<p>The paper addresses the challenge of systematically evaluating the clinical actionability of genomic variants identified incidentally or as secondary findings in genome-scale sequencing. It is situated within clinical genomic diagnostics, particularly in defining and standardizing which gene–disease pairs warrant routine reporting based on actionability.  </p>

<p><strong>Geographic/Institutional Context:</strong>  </p>

<p>University of North Carolina at Chapel Hill, USA  </p>

<p><strong>Target Users/Stakeholders:</strong>  </p>

<p>Clinical geneticists, genetic counselors, genomic laboratories, healthcare providers, professional organizations (e.g., ACMG), policy-makers.  </p>

<p><strong>Primary Methodology:</strong>  </p>

<p>Conceptual framework and scoring metric development, applied analysis of multiple gene lists  </p>

<p><strong>Primary Contribution Type:</strong>  </p>

<p>Development and validation of a semiquantitative scoring framework for clinical actionability  </p>

<hr />

<h2>General Summary of the Paper</h2>

<p>This paper presents a semiquantitative metric for evaluating the clinical actionability of incidental or secondary findings in genome-scale sequencing. Developed by the Locus-Variant Binning Committee (LVBC) of the NCGENES project, the metric assesses five elements—severity, likelihood, efficacy of intervention, burden of intervention, and strength of the knowledge base—each scored from 0 to 3, producing a total score from 0 to 15. The framework was applied to 161 provisionally actionable genes, the 57 ACMG-recommended genes, and 1,000 randomly selected genes, demonstrating the metric’s ability to discriminate between highly actionable and less actionable conditions. The authors propose a score of ≥11 as a threshold for high actionability and highlight the framework’s flexibility, transparency, and potential for adaptation across contexts.</p>

<hr />

<h2>Eligibility</h2>

<p>Eligible for inclusion: <strong>Yes</strong></p>

<hr />

<h2>How Actionability is Understood</h2>

<p>Actionability is conceptualized as a <strong>continuum</strong> rather than a binary state, integrating the potential severity and likelihood of adverse health outcomes, the effectiveness and acceptability of preventive or therapeutic interventions, and the strength of supporting evidence.  </p>

<blockquote>
  <p>“The LVBC developed a semiquantitative metric for determining the clinical actionability of gene–disease pairs. This metric explicitly recognizes that actionability is a continuum, not a binary state.” (p. 468)  </p>
</blockquote>

<blockquote>
  <p>“The subcategories… approximate the clinical utility of revealing incidental/secondary findings in a presymptomatic individual.” (p. 472)</p>
</blockquote>

<hr />

<h2>What Makes Something Actionable</h2>

<ul>
<li><p>High severity of the potential health outcome  </p></li>
<li><p>Moderate to high likelihood of disease manifestation  </p></li>
<li><p>Availability of effective preventive or therapeutic interventions  </p></li>
<li><p>Low burden or acceptable risk of intervention  </p></li>
<li><p>Substantial and reliable knowledge base supporting decision-making  </p></li>
</ul>

<hr />

<h2>How Actionability is Achieved / Operationalized</h2>

<ul>
<li><p><strong>Framework/Approach Name(s):</strong> Semiquantitative Metric for Clinical Actionability  </p></li>
<li><p><strong>Methods/Levers:</strong> Five criteria scored 0–3 (severity, likelihood, efficacy, burden, knowledge base)  </p></li>
<li><p><strong>Operational Steps / Workflow:</strong> Evidence review → Assign scores for each criterion → Consensus scoring by multidisciplinary panel → Total score calculation → Apply threshold (≥11) for actionability  </p></li>
<li><p><strong>Data &amp; Measures:</strong> Literature from OMIM, GeneReviews, PubMed, clinical guidelines  </p></li>
<li><p><strong>Implementation Context:</strong> NCGENES project and ACMG incidental findings recommendations  </p></li>
</ul>

<blockquote>
  <p>“All five criteria are scored on a scale of 0–3… The outcome and intervention are defined in advance… to balance clinical effects against benefits and harms.” (p. 469)  </p>
</blockquote>

<blockquote>
  <p>“The LVBC chose to consider genes with a score ≥11… as meeting the threshold of actionability.” (p. 472)</p>
</blockquote>

<hr />

<h2>Dimensions and Attributes of Actionability (Authors’ Perspective)</h2>

<ul>
<li><p><strong>CL (Clarity):</strong> Yes — Clarity through structured scoring definitions (Table 1)  </p></li>
<li><p><strong>CR (Contextual Relevance):</strong> Yes — Explicit to presymptomatic, incidental/secondary findings context  </p></li>
<li><p><strong>FE (Feasibility):</strong> Yes — Evaluated through “burden of intervention” score  </p></li>
<li><p><strong>TI (Timeliness):</strong> Partial — Implied in presymptomatic intervention consideration  </p></li>
<li><p><strong>EX (Explainability):</strong> Yes — Transparent, evidence-based scoring with defined criteria  </p></li>
<li><p><strong>GA (Goal Alignment):</strong> Partial — Implicit alignment with clinical utility and patient benefit  </p></li>
<li><p><strong>Other Dimensions Named by Authors:</strong> Knowledge base strength</p></li>
</ul>

<hr />

<h2>Theoretical or Conceptual Foundations</h2>

<ul>
<li><p>Clinical utility concepts from genomic medicine  </p></li>
<li><p>Evidence-based assessment models  </p></li>
<li><p>Prior ACMG deliberative consensus recommendations  </p></li>
</ul>

<hr />

<h2>Indicators or Metrics for Actionability</h2>

<ul>
<li><p>Total score (0–15)  </p></li>
<li><p>Threshold ≥11 for high actionability  </p></li>
<li><p>Subscores for severity, likelihood, efficacy, burden, and knowledge base  </p></li>
</ul>

<hr />

<h2>Barriers and Enablers to Actionability</h2>

<ul>
<li><p><strong>Barriers:</strong> Limited evidence base; subjective burden assessment; rare diseases with insufficient penetrance data  </p></li>
<li><p><strong>Enablers:</strong> Structured metric; multidisciplinary consensus; adaptability to different contexts  </p></li>
</ul>

<hr />

<h2>Relation to Existing Literature</h2>

<p>The paper builds on and critiques earlier expert consensus models like the ACMG recommendations, adding a reproducible, transparent, and adaptable scoring framework for actionability.</p>

<hr />

<h2>Summary</h2>

<p>This paper delivers a rigorous, transparent framework for assessing the clinical actionability of incidental or secondary genomic findings, operationalizing actionability as a multidimensional continuum. Its five equally weighted dimensions—severity, likelihood, efficacy, burden, and knowledge base—are scored to produce a composite metric (0–15). A threshold score of ≥11 designates high actionability. The framework is validated through comparative analysis of ACMG-recommended genes, provisionally actionable genes, and random genes, demonstrating clear discriminatory capacity. It is adaptable to various clinical and policy contexts, supports reproducibility, and allows for updates as knowledge evolves, marking a significant advance in standardized genomic reporting.</p>

<hr />

<h2>Scores</h2>

<ul>
<li><p><strong>Overall Relevance Score:</strong> 95 — Clear conceptualization of actionability as multidimensional, detailed definitions, and systematic feature set  </p></li>
<li><p><strong>Operationalization Score:</strong> 100 — Fully developed metric with applied examples and scoring workflow  </p></li>
</ul>

<hr />

<h2>Supporting Quotes from the Paper</h2>

<ul>
<li><p>“Actionability is a continuum, not a binary state.” (p. 468)  </p></li>
<li><p>“The LVBC established five core characteristics of clinical actionability…” (p. 469)  </p></li>
<li><p>“The LVBC chose to consider genes with a score ≥11… as meeting the threshold of actionability.” (p. 472)  </p></li>
</ul>

<hr />

<h2>Actionability References to Other Papers</h2>

<ul>
<li><p>ACMG Recommendations for Reporting of Incidental Findings (Green et al., 2013)  </p></li>
<li><p>Evidence-based Genomic Applications in Practice and Prevention Working Group (Goddard et al., 2013)  </p></li>
<li><p>NCGENES project preliminary outputs (Berg et al., 2013)</p></li>
</ul>
